NCT05549180View on ClinicalTrials.gov

Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities

PHASE4CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

October 6, 2022

Primary Completion Date

February 13, 2024

Study Completion Date

August 7, 2024

Conditions
HIV Infections
Interventions
DRUG

BIKTARVY 50Mg-200Mg-25Mg Tablet and Dovato placebo

The patients randomized to experimental arm will be randomized to Biktarvy + Dovato placebo

DRUG

Dovato 50Mg-300Mg Tablet + Biktarvy placebo

The patients randomized to comparador arm will be randomized to Dovato + Biktarvy placebo

Trial Locations (14)

Unknown

H. Universitario Son Espases, Palma de Mallorca

CHUAC, A Coruña

Hospital de Bellvitge, Barcelona

Hospital Universitario Reina Sofía, Córdoba

Fundacion Hospital Alcorcón, Madrid

H. Universitario Infanta Leonor, Madrid

Hospital Clínico San Carlos, Madrid

Hospital Puerta de Hierro, Madrid

Hospital Universitario La Paz, Madrid

Hospital Universitario La Princesa, Madrid

H. Costa del Sol, Marbella

Hospital Son Llatzer, Palma de Mallorca

H. Univ. Virgen Macarena, Seville

H. Clinico Univ. Lozano Blesa, Zaragoza

All Listed Sponsors
lead

Fundacion SEIMC-GESIDA

OTHER